ReviewBiosensors2025
SERS-Driven Evolution of Lateral and Vertical Flow Assays in Medical Diagnostics.
Review in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Application of Core-Shell Bimetallic Nanoparticles with Polydopamine-Assisted Nanogap in SERS-Based Lateral Flow Immunoassay of Prolactin.Sensors (Basel, Switzerland) · 2026Article
- Ultrasensitive electrochemical dipstick lateral flow immunoassay for extracellular vesicle quantification using starch-iodine functionalized gold nanoparticles.Mikrochimica acta · 2026Article
- A comprehensive review of lateral flow assays in rapid livestock and poultry disease diagnostics.Journal of advanced veterinary and animal research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surface-enhanced Raman scattering (SERS) has emerged as a powerful signal amplification strategy to address the inherent limitations of conventional flow-based diagnostic methods such as lateral flow analysis (LFA) and vertical flow analysis (VFA). By incorporating SERS-active nanostructures into these platforms, SERS-integrated LFA and VFA systems have significantly improved sensitivity, specificity, and multiplexing performance while maintaining the simplicity and portability of conventional approaches. In this review, we summarize recent advances in SERS-enhanced flow-based diagnostics with a focus on exogenous and endogenous disease detection. Exogenous targets include viral antigens, bacterial pathogens, and foodborne contaminants such as mycotoxins and antibiotic residues. Endogenous applications include therapeutic drug monitoring, inflammation profiling, cancer biomarker detection, and exosome-based molecular subtyping. We highlight the structural differences between LFA and VFA approaches and their impact on analytical performance, and explore the advantages of SERS-integrated platforms for rapid and multiplexed detection in complex biological matrices. Finally, we provide an overview of key technical challenges, such as signal reproducibility, matrix interference, and device integration, and discuss future directions for clinical implementation of SERS-based flow diagnostics in point-of-care settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.